Tag Archive for: HRR
ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/in Not PCa related/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/in Clinical Trial, Metastatic, Phase 1/by MaxTalazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2
/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/in Observational, Retrospective studies/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/in CRISPR, PARPi, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 48/2025 November 30, 2025
- Phase 1/2 Trial for MK-6070: A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers November 29, 2025
- UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December November 27, 2025
- Phase 2 Trial for The Combo Fasudil Hydrochloride Plus PD-1 Immune Checkpoint Blockade November 27, 2025